• First biocompatible pharmaceutical formulations progress to preclinical models
• New sustained-release drug delivery platforms for peptides and melanocortins
• Aim to predict drug release kinetics from new formulations
• Liquid formulation allows flexible dosing through adjusting injection volumes

CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug release profiles. A decade of investment in fundamental research & development in CLINUVEL's fully-owned Singaporean laboratories (VALLAURIX) has provided positive, consistent results demonstrating the potential for depot formulations to extend the duration of release of peptide drugs. CLINUVEL's formulation development has sought to lengthen the duration of time that peptides are detectable in blood levels and arrive at predictable kinetics - optimising patient exposure to active pharmaceutical ingredients while minimising dosing to achieve therapeutic effects. The advantage of the chosen biocompatible formulations under review is to facilitate flexible dosing by adjusting the injection volume for delivery of peptides to infants, children and adults according to body weight. If the technology is confirmed in vivo, the new depot formulations would serve as a platform for the delivery of various peptides, with an initial focus on melanocortins. The preclinical program for the first formulations is expected to complete in the second half of 2026.